Just more than a year after disclosing its plan to buy out Ascent Pediatrics Inc., thereby gaining the pediatric asthma drug Orapred and a 66-person sales force, BioMarin Pharmaceutical Inc. is laying off 58 people - mostly from that team - in response to the launch of two new generic forms of the corticosteroid. (BioWorld Today) Read More
